KCM
AKBA icon

Kennedy Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Kennedy Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-333,841
Closed -$754K – 602
2021
Q4 		$754K Sell
333,841
-34,033
-9% -$92.8K 0.02% 537
2021
Q3 		$1.06M Buy
+367,874
New +$1.05M 0.02% 518

Other funds holding AKBA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
OCM
Orchard Capital Management Chicago, Illinois $95.9M AUM 45.49% 1-Year Est. Return

Kennedy Capital Management's AKBA Position: Q1 2022 in Review

Kennedy Capital Management sold out of Akebia Therapeutics (AKBA) in Q1 2022, closing a stake of 333,841 shares — an estimated $754K sold.

Kennedy Capital Management first reported a position in AKBA in Q3 2021 and held it in 2 quarters. The position peaked at $1.06M in Q3 2021. 124 funds tracked by Wall St. Rank hold AKBA as of Q1 2022.

  • Kennedy Capital Management reported no remaining Akebia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Kennedy Capital Management sold 333,841 Akebia Therapeutics shares in Q1 2022, an estimated $754K.
  • Kennedy Capital Management first reported a position in Akebia Therapeutics in Q3 2021 and held it in 2 quarters.
  • Kennedy Capital Management's Akebia Therapeutics position peaked at $1.06M in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2022.

Based on Kennedy Capital Management's 13F filing for Q1 2022, filed 16 May 2022.